Eight NCAA residues, including d- and dl-amino acids, have been incorporated into icatibant, a bradykinin B2 receptor antagonist decapeptide [69], and d-amino acid containing peptides furnish candidate drugs to inhibit the aggregation of amyloid peptides in Alzheimer’s disease [70]. The gene discussed is BDKRB2; the disease is early-onset autosomal dominant Alzheimer disease.